Foghorn Therapeutics (FHTX) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 0.44.
- Foghorn Therapeutics' Equity Ratio fell 37687.41% to 0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44, marking a year-over-year decrease of 37687.41%. This contributed to the annual value of 0.16 for FY2024, which is 4061.66% up from last year.
- Latest data reveals that Foghorn Therapeutics reported Equity Ratio of 0.44 as of Q3 2025, which was down 37687.41% from 0.34 recorded in Q2 2025.
- Over the past 5 years, Foghorn Therapeutics' Equity Ratio peaked at 0.54 during Q1 2021, and registered a low of 0.44 during Q3 2025.
- In the last 5 years, Foghorn Therapeutics' Equity Ratio had a median value of 0.07 in 2023 and averaged 0.02.
- Per our database at Business Quant, Foghorn Therapeutics' Equity Ratio surged by 14649.48% in 2021 and then tumbled by 9769646.8% in 2023.
- Over the past 5 years, Foghorn Therapeutics' Equity Ratio (Quarter) stood at 0.19 in 2021, then crashed by 99.85% to 0.0 in 2022, then plummeted by 97696.47% to 0.27 in 2023, then soared by 40.62% to 0.16 in 2024, then tumbled by 172.85% to 0.44 in 2025.
- Its Equity Ratio was 0.44 in Q3 2025, compared to 0.34 in Q2 2025 and 0.24 in Q1 2025.